NewLink Genetics announced additional data from its Phase 2 clinical trial of its HyperAcute Pancreas cancer immunotherapy for the treatment of resected pancreatic cancer. The open-label, non-randomized, multicenter trial included 70 patients with surgically resectable pancreatic cancer who received the HyperAcute Pancreas immunotherapy in combination with standard adjuvant chemotherapy. The primary objective of the study was disease-free survival at 12 months. Based on positive data from this trial, NewLink is currently enrolling a nationwide Phase 3 clinical trial of HyperAcute Pancreas cancer immunotherapy in patients who have successfully undergone pancreatic surgical resection.
HyperAcute Pancreas investigational product consists of equal doses of two separate allogeneic pancreatic cancer cell lines engineered to express α-Gal.
For more information call (515) 296-5555 or visit www.linkp.com.